Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Traws Pharma Inc. focuses on the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This action is assigned to 1 distinct examiner, YOUNGBLOOD, WILLIAM JUSTIN. This suggests that the company's current prosecution strategy is centered on 1 specific pharmaceutical or biotechnological innovation.
The prosecution is occurring within 1 distinct art unit. YOUNGBLOOD, WILLIAM JUSTIN is the busiest examiner, managing 1 pending office action. This 1 examiner and 1 art unit account for the entire current pending workload for the company's portfolio. For a practitioner, this means that the prosecution process is centralized. The outcome of the company's current intellectual property efforts depends on navigating the specific requirements of 1 art unit and the individual review style of YOUNGBLOOD, WILLIAM JUSTIN.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18542101 | METHODS AND COMPOSITIONS FOR TREATING CANCER | YOUNGBLOOD, WILLIAM JUSTIN | 41d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18542101 | METHODS AND COMPOSITIONS FOR TREATING CANCER | YOUNGBLOOD, WILLIAM JUSTIN | 41d |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18542101 | METHODS AND COMPOSITIONS FOR TREATING CANCER | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102§103§112 | Non-Final OA | 41d | Pending | Dec 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial